Amgen: Apotex Lost Bet; Biosimilar Should Be Blocked
This article was originally published in Scrip
Executive Summary
With the FDA set to make a decision any day on whether it will approve Apotex Corp.'s pegfilgrastim biosimilar, Amgen Inc. is seeking to block the product from entering the US market for at least six months after the medicine gains the agency's blessing.